Carvedilol

CAS 72956-09-3 23 current records 9 historicalSmall Molecule

Who holds supplier records for Carvedilol? 23 organisations hold a current record for Carvedilol: an active US FDA Type II Drug Master File or a CEP. A further 9 organisations have only historical (inactive) DMF filings. 17 of them hold a valid EU Certificate of Suitability (18 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (15), Spain (1), Netherlands (1), Poland (1) and 5 other countries (5).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Carvedilol: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/carvedilol

Reading the evidence

  • 23 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    15 of the 23 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 14 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Carvedilol expires 11 Mar 2026. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (23)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Carvedilol. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Carvedilol sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (18)

Certificates of Suitability on the EDQM register for Carvedilol, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 27 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
KRKA TOVARNA ZDRAVIL D.D. NOVO MESTO Novo mestoSI
CEP 2001-294 - Rev 05
Carvedilol
Jul 2026Inspected Jul 2025
Slovenia
VIYASH SCIENTIFIC LIMITED HyderabadIN
CEP 2019-239 - Rev 02
Carvedilol
Jul 2026—
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2005-267 - Rev 08
Carvedilol
Jun 2026—
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Starogard GdanskiPL
CEP 2002-258 - Rev 10
Carvedilol
Apr 2026Inspected Jul 2026
Poland
EGIS PHARMACEUTICALS PLC. Budapest XHU
CEP 2016-314 - Rev 01
Carvedilol, Synthetic route B
Apr 2026Inspected Nov 2025
Hungary
MOEHS IBERICA S.L. RubiES
CEP 2002-089 - Rev 04
Carvedilol
Oct 2025—
TAPI NL B.V. AmsterdamNL
CEP 2003-048 - Rev 07
Carvedilol
Jul 2025—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2024-534 - Rev 00
Carvedilol, Process-II, micronised
Feb 2025—
CTX LIFESCIENCES PVT. LIMITED SuratIN
CEP 2014-201 - Rev 02
Carvedilol
Jan 2025—
ZYDUS LIFESCIENCES LIMITED VadodaraIN
R0-CEP 2021-109 - Rev 00
Carvedilol
May 2023—
SHODHANA LABORATORIES PRIVATE LIMITED HyderabadIN
R1-CEP 2008-259 - Rev 01
Carvedilol
Jul 2022—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. LinhaiCN
R1-CEP 2004-287 - Rev 05
Carvedilol
Jul 2021—
IPCA Laboratories Limited MumbaiIN
R1-CEP 2007-298 - Rev 01
Carvedilol
Jun 2019—
EGIS Pharmaceuticals PLC BudapestHU
R1-CEP 2003-042 - Rev 03
Carvedilol
Feb 2019—
CIPLA LIMITED MumbaiIN
R1-CEP 2005-124 - Rev 03
Carvedilol
Mar 2018—
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
R1-CEP 2004-230 - Rev 05
Carvedilol
Jul 2015—
CADILA PHARMACEUTICALS LIMITED AnkleshwarIN
R1-CEP 2006-083 - Rev 01
Carvedilol
Nov 2013—
F Hoffmann-La Roche Ltd. BaselCH
R1-CEP 2002-001 - Rev 03
Carvedilol
Jul 2012—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (9)

Organisations whose Type II DMFs for Carvedilol are no longer active. These show a past filing, not current supply.

Show all 9 historical records
  • India · Inactive DMF 22043 · filed Sept 2008
  • ROCHE DIAGNOSTICS GMBH
    Inactive DMF 20587 · filed Jun 2007
  • India · Inactive DMF 20308 · filed Feb 2007
  • United States · Inactive DMF 19936 · filed Nov 2006
  • ORCHID CHEMICALS AND PHARMACEUTICALS LTD
    Inactive DMF 19373 · filed Apr 2006
  • URQUIMA SA
    Inactive DMF 18158 · filed Mar 2005
  • India · Inactive DMF 17487 · filed Jun 2004
  • Inactive DMF 17405 · filed May 2004
  • Czechia · Inactive DMF 16530 · filed Apr 2003

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (56 listed products contain Carvedilol). The latest listed patent expires 11 Mar 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Carvedilol is a non-selective beta blocker with alpha-1 blocking activity primarily used for the treatment of mild to moderate congestive heart failure and hypertension. It helps to decrease heart rate and dilate blood vessels to improve blood flow.

Chemical identity

IUPAC name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
Canonical SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
InChIKey
OGHNVEJMJSYVRP-UHFFFAOYSA-N
Synonyms
Carvedilol, Coreg, artist, bm 14.190, bm-14-190, bm-14.190, bm-14190, c07ag02, coronis, dilatrend, dimitone, dq-2466

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
alpha-Adrenergic Blocker; beta-Adrenergic Blocker
Mechanism of action
Adrenergic alpha-Antagonists; Adrenergic beta1-Antagonists; Adrenergic beta2-Antagonists

Therapeutic areas

Cardiovascular DiseasesHeart FailureHypertension

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Carvedilol?

23 organisations hold an active US FDA Type II Drug Master File or a CEP for Carvedilol: APITORIA PHARMA PRIVATE LTD (India), Cadila Pharmaceuticals Limited (India), Ipca Laboratories Limited (India), MATRIX PHARMACORP PRIVATE LTD (India), MOEHS IBERICA SL (Spain), SHODHANA LABORATORIES LTD (India), Sun Pharmaceutical Industries Limited (India) and TAPI NL BV (Netherlands), and 15 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Carvedilol Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 19106), Cadila Pharmaceuticals Limited (DMF 18515, 28139), Ipca Laboratories Limited (DMF 20930), MATRIX PHARMACORP PRIVATE LTD (DMF 18499), MOEHS IBERICA SL (DMF 16044), SHODHANA LABORATORIES LTD (DMF 39938), Sun Pharmaceutical Industries Limited (DMF 17590) and TAPI NL BV (DMF 15865) and 9 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Carvedilol records mean?

9 organisations have only inactive Type II DMFs for Carvedilol. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Carvedilol have a European Certificate of Suitability?

Yes. 17 organisations hold a valid CEP for Carvedilol on the EDQM register, including KRKA TOVARNA ZDRAVIL D.D. NOVO MESTO Novo mesto (SI), VIYASH SCIENTIFIC LIMITED Hyderabad (IN), MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Starogard Gdanski (PL), EGIS PHARMACEUTICALS PLC. Budapest X (HU) and MOEHS IBERICA S.L. Rubi (ES) and 12 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Carvedilol?

Yes. The latest patent listed for an approved US product containing Carvedilol expires 11 Mar 2026, across 56 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Carvedilol supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Carvedilol?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.